Introduction
============

Colorectal cancer is among the leading causes of cancer death worldwide [@B1], [@B2]. In Korea and other East Asian countries, the incidence of colorectal cancer is increasing, which is attributed to changes in eating habits and popularization of cancer screening [@B1], [@B3]. In Korea, the incidence of colorectal cancer per 100,000 people was 21.8 in 2000, which steadily increased until 2012, peaking at 58.3 and declining slightly to 53.1 in 2014.

Colorectal cancer is closely related to obesity. In the second expert report co-published by the World Cancer Research Fund (WCRF) and the American Institute of Cancer Research (AICR), obesity was classified as a convincing risk factor that could cause colorectal cancer [@B4]. Obesity was also related with increased morbidity, mortality, and prolonged hospital stay in previous studies [@B5]-[@B7]. Gender is another factor known to affect colorectal cancer status. Some researchers have reported that the stage or location of colorectal cancer varies according to gender of patients [@B8], [@B9].

This study was performed to demonstrate the clinical significance of body mass index (BMI) and gender using a large nationwide colorectal cancer patients cohort of Korea.

Methods
=======

Data acquisition
----------------

The Korean government has operated the National Health Insurance Service (NHIS) for over 30 years, covering more than 98% of the population [@B10]. The Korean Health and Insurance Review and Assessment Service (HIRA) has recorded claims and reimbursements made under NHIS and provide information about healthcare services. Clinical data of colorectal cancer cohorts between 2012 and 2013 were acquired from HIRA (<http://opendata.hira.or.kr>). The cohorts provided data of patients who underwent surgery due to colorectal cancer. The acquired data included age, gender, height, weight, date of surgery, cancer stage, hospitalization period, and insurance codes of disease. Based on the insurance codes provided, the patients included in the cohort were diagnosed with malignant neoplasm of the colon (C18), malignant neoplasm of the rectosigmoid junction (C19), and malignant neoplasm of the rectum (C20).

Because not all colorectal cancer patients in Korea are included in the cohort, we referred to the national cancer incidence rate provided by the Korean Statistical Information Service [@B11] to determine the proportion of the cohort among the total colorectal cancer cases nationwide.

Cohort preparation for analysis
-------------------------------

The World Health Organization (WHO) criteria were used to classify BMI [@B12]: underweight was defined as BMI less than 18.5; normal weight 18.5-24.9; overweight, 25-29.9; and obese, 30 or above. The cases with insurance code C18 (malignant neoplasm of colon) were classified as proximal cancer, and the cases with C19 (malignant neoplasm of the rectosigmoid junction) or C20 (malignant neoplasm of the rectum) were categorized as distal cancer. Patients with stage IV in the cohorts were excluded from the analysis, because they might have heterogeneous nature such as much poor general condition, and the purpose of surgery might not be curative. If the patient records lack data in any of the variables, including height, weight, cancer stage, and hospitalization period, the records were excluded. Because the duration of the cohorts was as short as two years, and to maximize the statistical predictive power, statistical analysis was done with combined cohort summing cohorts of 2012 and 2013.

Statistical analysis
--------------------

Univariate analysis between BMI/gender with clinical variables, was performed using the Pearson chi-square test. Multivariate analysis was performed using logistic regression analysis. Regarding age groups, semantic interpretation was not made with multivariate analysis because certain age group could not represent a normal reference group. All analyses were performed using the IBM SPSS statistics 20 (IBM Inc., NY, US).

Results
=======

National incidence and evaluation of cohorts
--------------------------------------------

In 2012, the total number of colorectal cancer cases in Korea was 29,366 and was calculated as 58.3 cases per 100,000 people. At this year, HIRA recorded 18,310 patient cases, comprising 62.4% of the total national cases. A total of 2,169 stage IV cases and 409 patient records with missing data were excluded, and 15,732 patient records were finally included for analysis.

In 2013, 27,870 colorectal cancer cases occurred in Korea, which can be estimated to 55.1 cases per 100,000 people. The HIRA cohort comprised 66.1% with 18,430 patient records. After excluding 2,317 stage IV patient records and 89 records with missing data, 16,024 patient records were analyzed. Overall, a total of 31,756 colorectal cancer records, which accounted for 64.2% of all patients in the country, were used for analysis, including HIRA cohorts of 2012 and 2013.

Univariate analysis of BMI and clinical variables
-------------------------------------------------

The number of underweight, normal weight, overweight, and obese patients in the total cohort was 1670 (5.3%), 20,184 (63.6%), 8,946 (28.2%), and 956 (3.0%), respectively. When analyzing all four BMI groups, and between normal weight and the other three groups, statistically significant difference of distribution (p\<0.05) of clinical variables was noted in most of the analyses. Only the analyses comparing normal weight and underweight, normal weight and overweight regarding age, normal weight and overweight, and normal weight and obese assessing disease locations were not statistically significant. The results of initial analysis are described in Table [1](#T1){ref-type="table"}.

Multivariate analysis of BMI and clinical variables
---------------------------------------------------

The underweight group had high risk for advanced stage cancer. The risks of stage II and stage III disease were 67% and 33% higher in the underweight group than in the normal weight group, respectively (p\<0.001 and p\<0.001, respectively). The overweight and obese groups had a lower risk of having advanced stage cancer than the normal weight group. Compared with the normal weight group, the overweight group showed 20% lower risk to have both stage II and III cancer (p\<0.001 and p\<0.001, respectively), and the obese group showed 40% and 19% lower risk to have stage II and III cancer (p\<0.001 and p=0.007, respectively).

Hospitalization period was shown to be relatively short in the overweight group. The overweight group had a 22% lower risk for the highest quartile (days of hospital stay\>19 days) than the normal weight group (p\<0.001). The obese group had 33% high risk for the highest quartile (p=0.002). In the underweight group, the risk for the highest quartile was as high as 126% compared with that in the normal weight group (p\<0.001).

For gender, no difference was noted between the normal weight and underweight and normal weight and overweight groups. The number of female patients in the obese group was significantly higher than that in the normal weight group (p\<0.001; OR: 1.48; 95% confidence interval (CI): 1.30-1.68). Disease location was not significantly different in all analyses, including that in the normal weight compared with the underweight, overweight, and obese groups. The results of the above analysis are shown in Table [2](#T2){ref-type="table"}. Mean value distribution according to BMI categories of cancer stage and hospitalization period are exhibited in Figure [1](#F1){ref-type="fig"}.

Analysis of Gender and clinical variables
-----------------------------------------

The distribution of patients according to gender and the results of the univariate analysis are described in Table [3](#T3){ref-type="table"}. In comparison between genders, there were significant differences according to age group, BMI, and disease location (Ps\<0.001). Regarding age groups, the proportions of patients who were \<50 years and ≥70 years old were higher in the females, and the proportions of patients in their 50s and 60s were higher in the males (Figure [2](#F2){ref-type="fig"}). Cancer stage and hospitalization period showed no difference according to gender (p=0.111, 0.720, respectively). In multivariate analysis, the female cohort had more of obese patients (p\<0.001; OR 1.49; 95% CI 1.31 - 1.70), and less of distal colorectal cancer patients (p\<0.001; OR 0.88; 95% CI 0.84 - 0.92) than the male cohort. The results of multivariate analysis are also described in Table [3](#T3){ref-type="table"}.

Discussion
==========

This study showed clinical relevance of BMI and gender, with colorectal cancer of Asians. Cancer stage was higher in the underweight group and lower in the overweight and obese groups than in the normal weight group. Hospitalization period was longer than normal weight group, in the underweight and obese groups. In particular, the underweight group showed a significantly high risk of the top quartile of hospitalization period.

The research results on the relationship between obesity and cancer stage are conflicting. Some researchers suggested that high BMI might be associated with advanced colon cancer [@B8], [@B13], [@B14]. Other investigators have reported no association between obesity and colon cancer stage [@B15]-[@B17], and a recent meta-analysis indicated that BMI is not related to pathologic status of rectal cancer [@B6]. In our study, the risk of advanced cancer stage in the overweight or obese groups was lower than in the normal weight group. Although further investigation is needed to explain the result, we hypothesize that BMI categorization might be the partial cause of the difference from the previous studies. Most studies have described the distinctive status of diseases in obese populations, but the proportion of obese patients in our study was too small. It is also possible cause that we only did analysis using BMI, and did not perform body composition analysis [@B18], [@B19].

Conventional wisdom among surgeons is that obese patients have more medical comorbidities, and the risk of adverse surgical outcome is high [@B20]. A recent meta-analysis supported this theory with the result that obesity was related with increased risk of surgical complications [@B6]. However, some previous studies reported that obesity might not be a risk factor for increased hospitalization period or postoperative complications [@B21]-[@B23].

A recent study using the nationwide inpatient database of the US reported that preobese and obese patients had short hospitalization period [@B7]. However, the hospitalization period was increased at normal and severe obesity (BMI ≥40) groups, which was shown as a U-shaped curve. In our study, the overweight group had a shorter hospitalization period than the normal weight group, and the obese group had a high risk of long hospitalization period. The proportion of patients with BMI ≥30 was over 70% in the US study, whereas in our study it was only 3%. Considering that the BMI of Asian people is generally lower than that of Western people, and if we hypothesize that the obese group in our study and severe obesity group in the US study reflect similar biologic degree of obesity, the two studies might be regarded with similar context.

Although it is a less rigorously researched subject, being underweight is also a clinical concern in colorectal cancer. Mullen et al. [@B20] reported that underweight patients who underwent intra-abdominal cancer surgery have high postoperative mortality (odds ratio: 5.24; 95% CI: 1.70-16.2). Tjeertes et al. [@B24] also found that complication and morality rates were significantly worse in underweight patients who underwent general surgery.

Several explanations were suggested for this phenomenon. The underweight group may be composed of more smokers or people who have experienced weight loss due to chronic illness [@B25], [@B26]. Recent weight loss \>10% or low albumin levels have also been associated with postoperative morbidity and mortality [@B27]-[@B29]. In our study, the underweight group had increased risk of higher cancer stage, which might be associated with postoperative outcome and longer hospitalization period. Our results are consistent with previous studies.

Colorectal cancer is a disease closely associated with gender. In our study, the proportion of female patients was slightly higher in age group under 50 years, male patients were higher in groups of 50s and 60s, and female patients were higher in group over 70 years of age. The number of incidence were higher in the male patients across all age groups. This trend is consistent with the results of two large cohort studies using the United States Surveillance, Epidemiology and End Results (SEER) database [@B30], [@B31]. The cumulative protective effect of estrogen for up to 20-25 years after menopause, and reduction of colorectal cancer risk with use of hormone replacement therapy, have been suggested as hypotheses to explain these results [@B32]-[@B34].

Our study showed that female patients were less likely to have distal colon cancer than male patients. This finding is consistent with most of the related reports [@B8], [@B35]-[@B37]. Differences in lifestyle and eating habits [@B38]-[@B42], and differences in screening rates are possible explanations [@B30], [@B43], but further research is needed to find the reason for this result.

Male patients are generally known to have more advanced colorectal cancer [@B8], [@B44], [@B45]. A meta-analysis reported that male patients had more advanced stage of colorectal cancer than females [@B9]. The etiology for the gender difference is still uncertain, but preventive effect of estrogen and progestins [@B46], [@B47], less use of smoking and alcohol [@B48]-[@B50], and genetic difference have been suggested as possible hypotheses [@B44], [@B51].

In our study, multivariate analysis showed no significant difference in cancer stages, and proportions according to stages were almost similar between men and women. In a large epidemiologic study using the SEER database from 1975 to 2006, men had significantly higher incidence of colorectal cancer in all stages. However, the differences of incidence between men and women were 18.3%, 12.5% and 7.7%, in localized, regional, and distant stage of cancer, respectively; the differences were decreased as the disease were getting advanced [@B37]. Considering the results of our study and the SEER database study, further investigation might be needed about the past knowledge that male patients generally have a higher incidence of advanced colorectal cancer.

Several limitations should be taken into consideration to interpret the present study. Our study is mainly observational, and the analysis was performed with narrow range of clinical information. The main limitation of our study is that it is impossible to perform detailed analyses to clearly define the cause of results. Nevertheless, this study is still valuable for showing the clinical significance of BMI and gender in Asian patients with colorectal cancer, who have been less studied and may have different obesity characteristics from the Western population.

As socioeconomic status is known to be closely related to obesity [@B52], diagnostic chance from cancer screening might be increased in a certain BMI group. In Korea, the national cancer screening program has provided free services for those with bottom 50% income and subsidized 80% of costs for higher income group, from 2006 [@B53]. Considering a study about relationship between socioeconomic status and obesity of Koreans, dose-response relationship was noted between income and obesity for men but not for women [@B54]. However, numeral difference of median BMI between lowest and highest income quartile was only 1.4, and median values of BMI in all quartiles were narrowly ranged from 22.5 to 23.9. Although possible bias could not be fully controlled, the likelihood that obesity and related socioeconomic differences affect the screening chance and consequently affected the outcome of this study might be less than moderate.

Conclusion
==========

In our study, using WHO BMI classification, being obese or underweight was related with cancer stage and hospitalization period but not with tumor location. Underweight and obese patients showed prolonged hospitalization period, whereas preobese patients had shorter hospitalization period. Underweight patients had high cancer stages, whereas overweight and obese patients have low stages. Female patients had a lower incidence rate of distal colon cancer than male patients, and there was no significant correlation between cancer stage and gender. There were relatively more female patients in the \<50 and ≥70 of ages and more male patients in the 50s and 60s. Our study is one of the largest studies investigating clinical relevance of gender and BMI with colorectal cancer in Asians. Several distinctive results in our study offer possibilities of future research.
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###### 

Univariate analysis of body mass index and clinical variables

                                             Categories (body mass index)                                                                             
  ------------------------------- ---------- ------------------------------ --------------- -------------- ------------ --------- --------- --------- ---------
  Age                                                                                                                                                 
                                  \<50       178 (10.7)                     2,202 (10.9)    987 (11.0)     112 (11.7)                                 
                                  50 to 59   310 (18.6)                     4,772 (23.6)    2,199 (24.6)   261 (27.3)                                 
                                  60 to 69   458 (27.4)                     5,967 (29.6)    2,851 (31.9)   290 (30.3)                                 
                                  ≥70        724 (43.4)                     7,243 (35.9)    2,909 (32.5)   293 (30.6)   \<0.001   \<0.001   \<0.001   0.005
  Gender                                                                                                                                              
                                  Male       995 (59.6)                     12,249 (60.7)   5,427 (60.7)   491 (51.4)                                 
                                  Female     675 (40.4)                     7,935 (39.3)    3,519 (39.3)   465 (48.6)   \<0.001   0.374     0.971     \<0.001
  Cancer stage                                                                                                                                        
                                  I          276 (16.5)                     4,924 (24.4)    2,622 (29.3)   295 (30.9)                                 
                                  II         706 (42.3)                     6,722 (33.3)    2,781 (31.1)   241 (25.2)                                 
                                  III        688 (41.2)                     8,538 (42.3)    3,543 (39.6)   420 (43.9)   \<0.001   \<0.001   \<0.001   \<0.001
  Hospitalization period (days)                                                                                                                       
                                  \<11       336 (20.1)                     6,193 (30.7)    3,060 (34.2)   264 (27.6)                                 
                                  11 to 13   326 (19.5)                     4,956 (24.6)    2,229 (24.9)   259 (27.1)                                 
                                  14 to 18   366 (21.9)                     4,221 (20.9)    1,887 (21.1)   185 (19.4)                                 
                                  ≥19        642 (38.4)                     4,814 (23.9)    1,770 (19.8)   248 (25.9)   \<0.001   \<0.001   \<0.001   0.047
  Location of disease                                                                                                                                 
                                  Proximal   626 (37.5)                     6,926 (34.3)    3,067 (34.3)   312 (32.6)                                 
                                  Distal     1,044 (62.5)                   13,258 (65.7)   5,879 (65.7)   644 (67.4)   0.037     0.009     0.959     0.285
                                                                                                                                                      
  Total                                      1,670 (100)                    20,184 (100)    8,946 (100)    956 (100)    31,756                        

Abbreviations: UW, underweight; NO, normal weight; OW, overweight; OB, obese

###### 

Multivariate analysis of body mass index and clinical variables

                                             NW (18.5-24.9) compared with                                                             
  ------------------------------- ---------- ------------------------------ --------- ------------------ --------- ------------------ ---------
  Age                                                                                                                                 
                                  \<50       ref                                      ref                          ref                
                                  50 to 59   0.80 (0.66-0.97)               0.024                        0.658                        0.438
                                  60 to 69                                  0.358                        0.142                        0.934
                                  ≥70                                       0.267                        0.059     0.79 (0.63-1.00)   0.044
  Gender                                                                                                                              
                                  Male       ref                                      ref                          ref                
                                  Female                                    0.569                        0.579     1.48 (1.30-1.68)   \<0.001
  Cancer stage                                                                                                                        
                                  I          ref                                      ref                          ref                
                                  II         1.67 (1.44-1.93)               \<0.001   0.80 (0.75-0.86)   \<0.001   0.60 (0.50-0.71)   \<0.001
                                  III        1.33 (1.15-1.53)               \<0.001   0.80 (0.75-0.85)   \<0.001   0.81 (0.69-0.94)   0.007
  Hospitalization period (days)                                                                                                       
                                  \<11       ref                                      ref                          ref                
                                  11 to 13   1.18 (1.01-1.39)               0.035     0.92 (0.86-0.98)   0.013     1.26 (1.06-1.50)   0.010
                                  14 to 18   1.51 (1.29-1.76)               \<0.001   0.93 (0.87-1.00)   0.045                        0.356
                                  ≥19        2.26 (1.96-2.59)               \<0.001   0.78 (0.72-0.83)   \<0.001   1.33 (1.11-1.60)   0.002
  Location of disease                                                                                                                 
                                  Proximal   ref                                      ref                          ref                
                                  Distal                                    0.243                        0.511                        0.513

Abbreviations: UW, underweight; OR, odd ratio; CI, confidence interval; NO, normal weight; OW, overweight; OB, obese

###### 

Analyses between gender and clinical variables

                                          Univariate analysis                 Multivariate analysis (compared to male)                        
  ----------------------- --------------- --------------------- ------------- ------------------------------------------ -------------------- ---------
  Age                                                                                                                                         
                          \<50            1942 (10.1)           1537 (12.2)                                              ref                  
                          50 to 59        4718 (24.6)           2824 (22.4)                                              0.76 (0.70 - 0.82)   \<0.001
                          60 to 69        6324 (33.0)           3242 (25.7)                                              0.65 (0.60 - 0.70)   \<0.001
                          ≥70             6178 (32.2)           4991 (39.6)   \<0.001                                                         0.586
  BMI                                                                                                                                         
                          Normal weight   12249 (63.9)          7935 (63.0)                                              ref                  
                          Underweight     995 (5.2)             675 (5.4)                                                                     0.727
                          Overweight      5427 (28.3)           3519 (27.9)                                                                   0.55
                          Obese           491 (2.6)             465 (3.7)     \<0.001                                    1.49 (1.31 - 1.70)   \<0.001
  Cancer stage                                                                                                                                
                          I               4963 (25.9)           3154 (25.0)                                              ref                  
                          II              6322 (33.0)           4128 (32.8)                                                                   0.929
                          III             7877 (41.1)           5312 (42.2)   0.111                                                           0.09
  Hopitalization period                                                                                                                       
                          \<11            5969 (31.2)           3884 (30.8)                                              ref                  
                          11 to 13        4714 (24.6)           3056 (24.3)                                                                   0.912
                          14 to 18        4001 (20.9)           2658 (21.1)                                                                   0.962
                          ≥19             4478 (23.4)           2996 (23.8)   0.720                                                           0.603
  Location of disease                                                                                                                         
                          Proximal        6362 (33.2)           4569 (36.3)                                              ref                  
                          Distal          12800 (66.8)          8025 (63.7)   \<0.001                                    0.88 (0.84 - 0.92)   \<0.001
  Total                                   19,162                12594                                                                         

Abbreviations: OR, odd ratio; CI, confidence interval; BMI, body mass index

[^1]: Competing Interests: The authors have declared that no competing interest exists.
